TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Vistin Pharma ASA
Closing information (x1000 NOK)
| Closing information | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
429,091
|
435,391
|
287,675 |
| Financial expenses |
14,557
|
30,920
|
9,466 |
| Earnings before taxes |
80,454
|
58,518
|
-6,008 |
| Total assets |
384,944
|
403,396
|
407,214 |
| Current assets |
143,187
|
168,774
|
159,182 |
| Current liabilities |
63,968
|
69,474
|
117,795 |
| Equity capital |
309,529
|
322,770
|
273,263 |
| - share capital |
44,345
|
44,345
|
44,345 |
| Employees (average) | 0 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
80.4%
|
80.0%
|
67.1% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
18.7%
|
13.4%
|
-2.1% |
| Return on assets (ROA) |
24.7%
|
22.2%
|
0.8% |
| Current ratio |
223.8%
|
242.9%
|
135.1% |
| Return on equity (ROE) |
26.0%
|
18.1%
|
-2.2% |
| Change turnover |
-6,300
|
147,716
|
11,863 |
| Change turnover % |
-1%
|
51%
|
4% |
| Chg. No. of employees | |||
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.